Research team describes novel tumor treatment

November 24, 2015, Virginia Tech
Gliobastoma (astrocytoma) WHO grade IV - MRI coronal view, post contrast. 15 year old boy. Credit: Christaras A/ Wikipedia.

In the first published results from a $386,000 National Cancer Institute grant awarded earlier this year, a paper by Scott Verbridge and Rafael Davalos in Scientific Reports has been published.

The paper—co-written by John Rossmeisl , Virginia-Maryland College of Veterinary Medicine associate professor of internal medicine and neurology; Michael Sano, postdoctoral researcher at Stanford; and Virginia Tech Department of Biomedical Engineering and Mechanics Ph.D. students Jill Ivey of Fayetteville, Arkansas and Eduardo Latouche of Valencia, Venezuela,—describes the researchers' work on developing a new type of treatment for glioblastoma multiforme (GBM), the most common and deadly malignant primary brain tumor.

Patients with glioblastoma have a five-year survival rate of less than 10 percent, Verbridge said.

"This statistic has not improved significantly in decades, and there is still no treatment option to preferentially target the glioma stem cells or diffuse infiltrative cells that lead to tumor recurrence after surgery, chemo, or radiotherapy," Verbridge said.

The paper, "Targeted cellular ablation based on the morphology of malignant cells," describes research into a new treatment option involving pulsed electric fields (PEFs) that is better at targeting and killing malignant cells while leaving alive.

Glioblastoma is particularly resistant to conventional and targeted cancer therapies, in part because tumors are made up of cells that are very different from one another. Surgical, chemical, radiation, and molecular treatments all have shortcomings that make it difficult to target malignant cells without damaging critical surrounding structures or prompting the emergence of therapy-resistant cells.

Recurrence after initial treatment is extremely common as a result.

In their work, Verbridge and Davalos are building on a technique patented by Davalos involving irreversible electroporation (IRE) of tumor cells by inserting electrodes directly into a tumor. This treatment has been successfully used to treat canine patients with similar brain tumors.

Verbridge and Davalos have developed a high-frequency version of this therapy (HFIRE) that uses pulses delivered in a rapid burst. IRE and HFIRE are both capable of killing tumor cells, but the mechanism differs, the researchers found. IRE appears to cause cellular death by disrupting the outer cell membrane. HFIRE, in contrast, appears to also cause nuclear collapse. Mathematical models developed by the researchers predicted that the nuclear damage should scale with size of the nucleus relative to the cell.

Because HFIRE targets the nucleus, the researchers hypothesized that malignant cells, which have larger nuclei compared to in many cancers including glioblastoma, would have a lower threshold for a lethal burst.

Therefore, properly tuned HFIRE could target while leaving normal, healthy cells unharmed.

This was confirmed using 3-D tissue models consisting of co-cultures of normal and malignant brain cells. "We're essentially destroying based on their altered morphologies, specifically their enlarged nucleus-to-cytoplasm ratio which has been known for decades to be a strong indicator of malignancy in many cancers. This is a completely different potential approach to targeted therapy," Verbridge said.

Future experiments in vivo will be necessary to determine exactly how selective HFIRE ablation therapy will be, but the researchers expressed confidence that such a therapy, either on its own or in combination with other treatments, could be effective at killing the invasive glioblastoma that so often lead to tumor recurrence after initial rounds of treatment.

Explore further: Dog's successful surgery sets stage for treating humans

More information: Targeted cellular ablation based on the morphology of malignant cells, Scientific Reports, 2015.

Related Stories

Dog's successful surgery sets stage for treating humans

February 19, 2015
Almost five years ago, a 7-year-old Labrador retriever was operated on using a technique eventually patented by Virginia Tech biomedical engineering faculty member Rafael Davalos. The beloved family pet suffer from a cancerous ...

Researchers create a promising new treatment for the deadliest form of brain cancer

September 2, 2015
UCLA scientists have developed a potentially promising new combination therapy for glioblastoma, the most common and deadliest form of brain cancer.

Researchers find way to make resistant brain cancer cells sensitive to treatment

November 16, 2015
Scientists from the Virginia Tech Carilion Research Institute and clinicians from Carilion Clinic have discovered how to sensitize drug-resistant human glioblastoma cells to chemotherapy.

Virus-drug combination shows improved effectiveness against brain tumor cells

October 6, 2015
A rabbit virus currently being developed for cancer therapy can be paired with one of several existing drugs to deliver a more potent punch to a deadly type of brain tumor cell, researchers have found.

Researchers target cancer stem cells in malignant brain tumors

January 6, 2014
Researchers at the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Department of Neurosurgery identified immune system targets on cancer stem cells – cells from which malignant brain tumors are believed to originate ...

Team identifies drug that could limit the spread of deadly brain tumors

November 12, 2015
In a significant breakthrough, the Translational Genomics Research Institute (TGen) has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer.

Recommended for you

Researchers suggest new treatment for rare inherited cancers

July 16, 2018
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...

Researchers map 'family trees' of acute myeloid leukemia

July 16, 2018
For the first time, a team of international researchers has mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains ...

Scientists sharpen the edges of cancer chemotherapy with CRISPR

July 13, 2018
Tackling unsolved problems is a cornerstone of scientific research, propelled by the power and promise of new technologies. Indeed, one of the shiniest tools in the biomedical toolkit these days is the genome editing system ...

Products of omega-3 fatty acid metabolism may have anticancer effects, study shows

July 13, 2018
A class of molecules formed when the body metabolizes omega-3 fatty acids could inhibit cancer's growth and spread, University of Illinois researchers report in a new study in mice. The molecules, called endocannabinoids, ...

Looking at the urine and blood may be best in diagnosing myeloma

July 13, 2018
When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, ...

Massive genome havoc in breast cancer is revealed

July 12, 2018
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations—larger-scale rearrangements of DNA that can encompass large chunks of chromosomes—disturb carefully balanced mechanisms that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.